Jasper’s drug pipeline will address unmet needs in breast/lung/ovarian/pancreatic cancer drugs market and multidrug-resistant cancer drugs market. Both the markets are part of the broader cancer drugs market with £100+ billion
Breast cancer drugs is a £15 billion market expected to grow at 11% CAGR from 2017-23. The market is divided into chemotherapeutic drugs, hormone therapy drugs and targeted therapy drugs. Current market leaders are AstraZeneca, Celgene, Roche and others.
Lung cancer drugs is a £16 billion market expected to grow at 13% CAGR from 2017-23. The market is divided into chemotherapy drugs, immunotherapy and targeted therapy. Current market leaders are F. Hoffmann-La Roche, Novartis, Pfizer, Merck, Bristol-Myers Squibb, Sanofi and others.
Ovarian cancer drugs is a 1.5 billion market expected to grow at 24% CAGR from 2017-23. Rising incidence of ovarian cancer, owing to